Veterans Affairs Medical Center, Kansas City, Missouri; University of Kansas School of Medicine, Kansas City, Kansas, Missouri.
University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
Gastroenterology. 2012 Sep;143(3):564-566.e1. doi: 10.1053/j.gastro.2012.04.051. Epub 2012 May 3.
Patients with Barrett's esophagus are frequently treated with radiofrequency ablation (RFA). Those that undergo this procedure have a low risk of developing subsquamous intestinal metaplasia, and none have been reported to develop subsquamous dysplasia or cancer. We report the development of subsquamous neoplasia in 3 patients who were treated with RFA for Barrett's esophagus (2 developed adenocarcinoma and 1 developed high-grade dysplasia). The identification of these cases indicates the need for continued surveillance following RFA, even after complete eradication of intestinal metaplasia, and caution for widespread use of ablation, especially in patients with low-risk Barrett's esophagus.
接受射频消融 (RFA) 治疗的巴雷特食管患者常发生。这些患者发生黏膜下固有层异型增生的风险较低,且无一例发生黏膜下异型增生或癌症。我们报告了 3 例因巴雷特食管而行 RFA 治疗后发生黏膜下肿瘤的患者(2 例发展为腺癌,1 例发展为高级别异型增生)。这些病例的发现表明,即使在完全消除肠化生后,仍需要对 RFA 后进行持续监测,并对消融的广泛应用保持谨慎,尤其是在低危巴雷特食管患者中。